Results 141 to 150 of about 61,634 (258)

Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. [PDF]

Eurasian J Med, 2022
Kocak MN, Ates O, Hacımuftuoglu A, Ates I, Tekin E, Ceylan O, Okkay U.   +6 more
europepmc   +1 more source

Effect of Salinity Stress on Gut–Brain–Gonad Axis in the Red‐Eared Slider (Trachemys scripta elegans)

Integrative Zoology, EarlyView.
The increase in salinity leads to changes in the gut microbiota and metabolites of Trachemys scripta elegans, affecting the synthesis and secretion of neurotransmitters or precursors, which can inhibit the secretion of reproductive hormones and affect the self‐renewal and differentiation process of spermatogonial stem cells.
Qiongyu Zhang, Na Li, Xue Tang, Hanru Chen, Meiling Hong, Li Ding   +5 more
wiley   +1 more source

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine. [PDF]

BMC Cardiovasc Disord, 2021
Clausen MF, Rørth R, Torp-Pedersen C, Westergaard LM, Weeke PE, Gislason G, Køber L, Fosbøl E, Kristensen SL.   +8 more
europepmc   +1 more source

Effect of Social Rank on Gut Microbes and Their Metabolites of Greater Long‐Tailed Hamsters (Tscherskia triton)

Integrative Zoology, EarlyView.
Social rank in greater long‐tailed hamsters (Tscherskia triton) shapes gut microbiota composition and metabolite profiles. Dominant males exhibit a “high‐vigilance, metabolically activated” phenotype, with elevated aggression and specific gut microbiota enriched in energy‐harvesting taxa and fecal queuine.
Da Zhang, Xiaoming Xu, Zhibin Zhang
wiley   +1 more source

Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double‐Blind Primary Endpoint

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objective Published reports on directional deep brain stimulation (DBS) have been limited to small, single‐center investigations. Therapeutic window (TW) is used to describe the range of stimulation amplitudes achieving symptom relief without side effects.
Alfons Schnitzler, Pablo Mir, Matthew A. Brodsky, Leonard Verhagen, Sergiu Groppa, Ramiro Alvarez, Andrew Evans, Marta Blazquez, Sean Nagel, Julie G. Pilitsis, Monika Pötter‐Nerger, Winona Tse, Leonardo Almeida, Nestor Tomycz, Joohi Jimenez‐Shahed, Witold Libionka, Fatima Carrillo, Christian J. Hartmann, Stefan Jun Groiss, Martin Glaser, Florence Defresne, Edward Karst, Binith Cheeran, Jan Vesper, for the PROGRESS Study Investigators   +24 more
wiley   +1 more source

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma. [PDF]

Cureus, 2021
Khalil G, Khan FA, Jamal QM, Saleem A, Masroor H, Abbas K.   +5 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas. [PDF]

Endocr Oncol
Mignone E, Jukes AK, Valentine R, Allison R, De Sousa SMC.   +4 more
europepmc   +1 more source

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. [PDF]

BMC Endocr Disord, 2021
Zou Y, Li D, Gu J, Chen S, Wen X, Dong J, Jiang X.   +6 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source